KAIROS PHARMA, LTD. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
KAIROS PHARMA, LTD. (KAPA) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of $66.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-12
- KAIROS PHARMA, LTD. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$125.00K.
- KAIROS PHARMA, LTD. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $191.00K.
- KAIROS PHARMA, LTD. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$203.00K, a 177.78% decline year-over-year.
- KAIROS PHARMA, LTD. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$274.00K.
- KAIROS PHARMA, LTD. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was -$793.00K, a 296.29% decline from fiscal 2024.
- KAIROS PHARMA, LTD. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was $404.00K, a 47.67% decline from fiscal 2023.
- KAIROS PHARMA, LTD. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2023 was $772.00K.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$125.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $66.00K 10-Q · filed 2026-08-12 | -$137.00K derived: sum of 3 quarters · filed 2026-08-12 | -$411.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $191.00K 10-Q · filed 2026-05-13 | -$12.00K derived: sum of 2 quarters · filed 2026-05-13 | -$286.00K derived: sum of 3 quarters · filed 2026-05-13 | -$415.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$477.00K derived: sum of 2 quarters · filed 2026-03-31 | -$606.00K derived: sum of 3 quarters · filed 2026-08-12 | -$793.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$274.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$403.00K derived: sum of 2 quarters · filed 2026-08-12 | -$590.00K 10-Q · filed 2025-11-14 | -$329.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$129.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$316.00K 10-Q · filed 2026-08-12 | -$55.00K derived: sum of 3 quarters · filed 2026-08-12 | -$246.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$187.00K 10-Q · filed 2026-05-13 | $74.00K derived: sum of 2 quarters · filed 2026-05-13 | -$117.00K derived: sum of 3 quarters · filed 2026-05-13 | -$93.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $261.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $70.00K derived: sum of 2 quarters · filed 2026-03-31 | $94.00K derived: sum of 3 quarters · filed 2026-03-31 | $404.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$191.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$167.00K derived: sum of 2 quarters · filed 2025-11-14 | $143.00K 10-Q · filed 2025-11-14 | $339.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $334.00K 10-Q · filed 2025-08-12 | $530.00K derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $310.00K 10-Q · filed 2025-05-14 | $506.00K derived: sum of 2 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $196.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $772.00K 10-K · filed 2025-04-15 | ||
| 2023-09-30 | $576.00K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |